Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor α - benralizumab.

导出 LinkOut

翻译打印收藏纠错

作者： Joanna,Kosałka-Węgiel ^[1] ; Mamert,Milewski ^[2] ; Andżelika,Siwiec ^[2] ; Magdalena,Strach ^[1] ; Bogdan,Ochrem ^[2] ; Mariusz,Korkosz ^[1]

作者单位： Department of Rheumatology and Immunology, Jagiellonian University Medical College, Kraków, Poland. ^[1] 2nd Department of Internal Medicine, University Hospital, Kraków, Poland. ^[2] Department of Hematology, University Hospital, Kraków, Poland. ^[3]

关键词 HES IL-5 IL-5 receptor benralizumab hypereosinophilic syndrome monoclonal antibody

DOI 10.5114/ceji.2021.108259

PMID 34764813

发布时间 2021-11-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Central-European journal of immunology

2021年46卷3期

395-397页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor α - benralizumab.

Central-European journal of immunology

相似文献

Central-European journal of immunology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor α - benralizumab.

Central-European journal of immunology

相似文献

Central-European journal of immunology

相关期刊

检索历史清除